Yahoo
NYSE - BOATS Real Time Price USD

Annovis Bio, Inc. (ANVS)

1.1300 +0.1100 (+10.78%)
At close: October 30 at 4:00:03 PM EDT
1.1300 0.0000 (0.00%)
Overnight: 8:16:00 PM EST
Chart Range Bar
Loading chart for ANVS
Chart does not reflect overnight price.
  • Previous Close 1.0200
  • Open 1.0200
  • Bid 1.1100 x 110000
  • Ask 1.1500 x 340000
  • Day's Range 1.0100 - 1.1700
  • 52 Week Range 0.9300 - 5.5000
  • Volume 1,481,660
  • Avg. Volume 902,764
  • Market Cap (intraday) 48.227M
  • Beta (5Y Monthly) 1.23
  • PE Ratio (TTM) --
  • EPS (TTM) -1.7500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 10.50
  • Zacks Rating Neutral

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

www.annovisbio.com

7

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANVS
67.34%
S&P 500 (^GSPC)
10.73%

1-Year Return

ANVS
45.67%
S&P 500 (^GSPC)
11.11%

3-Year Return

ANVS
86.13%
S&P 500 (^GSPC)
81.91%

5-Year Return

ANVS
95.74%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -17.61M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

7.00
10.50 Average
1.1300 Current
17.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/28/2026
Analyst Roth Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 8 -> 7

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    48.23M

  • Enterprise Value

    29.50M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    16.34

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -142.36%

  • Return on Equity (ttm)

    -703.68%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -49.52M

  • Diluted EPS (ttm)

    -1.7500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.73M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -23.79M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.1300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: